Probiotics in the treatment of otitis media. The past, the present and the future.


Journal

International journal of pediatric otorhinolaryngology
ISSN: 1872-8464
Titre abrégé: Int J Pediatr Otorhinolaryngol
Pays: Ireland
ID NLM: 8003603

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 29 08 2018
revised: 16 10 2018
accepted: 16 10 2018
entrez: 18 12 2018
pubmed: 18 12 2018
medline: 29 1 2019
Statut: ppublish

Résumé

Otitis media (OM) is one of the most common infectious diseases in children and the leading cause for medical consultations and antibiotic prescription in this population. The burden of disease associated with OM is greater in developing nations and indigenous populations where the associated hearing loss contributes to poor education and employment outcomes. Current treatment and prevention is largely focused on vaccination and antibiotics. However, rates of OM, particularly in indigenous populations, remain high. With growing concerns regarding antibiotic resistance and antibiotic-associated complications, an alternative, more effective treatment is required. Administration of probiotics, both locally and systemically have been investigated for their ability to treat and prevent OM in children. This review explores the theoretical bases of probiotics, successful application of probiotics in medicine, and their use in the treatment and prevention of OM. We conclude that local administration of niche-specific probiotic bacteria that demonstrates the ability to inhibit the growth of otopathogens in vitro shows promise in the prevention and treatment of OM and warrants further investigation.

Identifiants

pubmed: 30554684
pii: S0165-5876(18)30535-4
doi: 10.1016/j.ijporl.2018.10.023
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-140

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Andrea Coleman (A)

The Centre for Children's Health Research, 62 Graham Street, South Brisbane, QLD, 4101, Australia; The University of Queensland Centre for Clinical Research, Herston, Australia. Electronic address: a.coleman2@uq.edu.au.

Anders Cervin (A)

The Royal Brisbane and Women's Hospital, Brisbane, Australia; The University of Queensland Centre for Clinical Research, Herston, Australia. Electronic address: a.cervin@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH